A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas

American Journal of Surgical Pathology

Volumn 34, Issue 7, 2010, Pages 915-926

  Kong, Christina S ^a   Beck, Andrew H ^a   Longacre, Teri A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adenocarcinoma; adenoma malignum; endocervix; endometrium; estrogen receptor; HPV ISH; minimal deviation; monoclonal CEA; p16; ProExC; progesterone receptor; vimentin

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER; VIMENTIN; VIRUS DNA;

ADENOCARCINOMA; ARTICLE; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; IN SITU HYBRIDIZATION; METABOLISM; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; REPRODUCIBILITY; TISSUE MICROARRAY; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VIMENTIN;

EID: 77954213971     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181e3291e     Document Type: Article

References (34)

1. Albores-Saavedra J, Martinez-Benitez B, Luevano E. Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol. 2008;27:333-339.
2. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 2003;442:271-277.
3. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochem-ical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol. 2004;28:160-167.
4. Aximu D, Azad A, Ni R, et al. A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and mini-chromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol. 2009;28:114-119.
5. Badr RE, Walts AE, Chung F, et al. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol. 2008;32:899-906.
6. Castrillon DH, Lee KR, Nucci MR. Distinction between endome-trial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002;21:4-10.
7. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohisto-chemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007;26:328-333. (Pubitemid 46986071)
8. Conesa-Zamora P, Domenech-Peris A, Orantes-Casado FJ, et al. Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am J Clin Pathol. 2009;132:378-390.
9. Conesa-Zamora P, Domenech-Peris A, Ortiz-Reina S, et al. Immunohistochemical evaluation of ProEx C in human papilloma-virus-induced lesions of the cervix. J Clin Pathol. 2009;62:159-162.
10. Dabbs DJ, Sturtz K, Zaino RJ. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol. 1996;27:172-177.
11. DiVito KA, Charette LA, Rimm DL, et al. Long-term preservation of antigenicity on tissue microarrays. Lab Invest. 2004;84:1071-1078.
12. Ferguson AW, Svoboda-Newman SM, Frank TS. Analysis of human papillomavirus infection and molecular alterations in adenocarcinoma of the cervix. Mod Pathol. 1998;11:11-18.
13. Fukushima M, Shimano S, Yamakawa Y, et al. The detection of human papillomavirus (HPV) in a case of minimal deviation adenocarcinoma of the uterine cervix (adenoma malignum) using in situ hybridization. Jpn J Clin Oncol. 1990;20:407-412.
14. Grayson W, Taylor LF, Cooper K. Adenoid basal carcinoma of the uterine cervix: detection of integrated human papillomavirus in a rare tumor of putative "reserve cell" origin. Int J Gynecol Pathol. 1997;16:307-312.
15. Herrington CS, Graham D, Southern SA, et al. Loss of retino-blastoma protein expression is frequent in small cell neuroendocrine carcinoma of the cervix and is unrelated to HPV type. Hum Pathol. 1999;30:906-910.
16. Horn LC, Lindner K, Szepankiewicz G, et al. p16, p14, p53, and cyclin D1 expression and HPV analysis in small cell carcinomas of the uterine cervix. Int J Gynecol Pathol. 2006;25:182-186.
17. Ihaka R, Gentleman RR. A language for data analysis and graphics. J Computational Graphical Statist. 1996;5:299-314.
18. Kamoi S, AlJuboury MI, Akin MR, et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol. 2002;21:217-223.
19. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284.
20. Kurman RJ, Norris HJ, Wilkinson E. Minimal Deviation Adeno-carcinoma. Tumors of the Cervix, Vagina, and Vulva. Washington, D.C: AFIP; 1992;91-93.
21. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 2002;161: 1557-1565.
22. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarci-noma. Int J Gynecol Pathol. 2003;22:231-235.
23. McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002;21:11-15.
24. Mikami Y, Kiyokawa T, Hata S, et al. Gastrointestinal immuno-phenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and 'adenoma malignum'. Mod Pathol. 2004;17:962-972.
25. Pinto AP, Schlecht NF, Woo TY, et al. Biomarker (ProEx C, p16(INK4A), and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod Pathol. 2008;21:1067-1074.
26. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157:1055-1062.
27. Riethdorf L, Riethdorf S, Lee KR, et al. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol. 2002;33:899-904.
28. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741-1748.
29. Staebler A, Sherman ME, Zaino RJ, et al. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol. 2002;26:998-1006.
30. Toki T, Zhai YL, Park JS, et al. Infrequent occurrence of high-risk human papillomavirus and of p53 mutation in minimal deviation adenocarcinoma of the cervix. Int J Gynecol Pathol. 1999;18: 215-219.
31. Walts AE, Bose S. p16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia. Hum Pathol. 2009;40:957-964.
32. Xu JY, Hashi A, Kondo T, et al. Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia. Int J Gynecol Pathol. 2005;24: 296-302.
33. Yemelyanova A, Ji H, Shih IM, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endome-trioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33:1504-1514.
34. Yemelyanova A, Vang R, Seidman JD, et al. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol. 2009;33:914-924.